|
May 26, 2020
|
Sesen Bio to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Jefferies Virtual Healthcare
|
|
May 11, 2020
|
Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability
Manufacturing and release testing of the Fujifilm pre-PPQ batch completed successfully Positive Interactions with EMA on Regulatory Pathway for Vicinium ® in Europe Market research conducted in 1Q 2020 supports Urologists prefer Vicinium to Keytruda ® CAMBRIDGE, Mass.
|
|
May 7, 2020
|
Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium®
No additional clinical trials were requested by the CHMP for submission of Vicinium marketing authorization application Anticipated submission of marketing authorization application in early 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical
|
|
May 4, 2020
|
Sesen Bio to Host Conference Call to Review First Quarter Financial Results and to Provide Operational Update Highlighting Positive Progress Towards Demonstrating Analytical Comparability
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 11,
|
|
Mar 16, 2020
|
Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results
Company on track to complete Vicinium ® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted
|
|
Feb 25, 2020
|
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell , President and CEO, will host a conference call on Monday,
|
|
Feb 24, 2020
|
Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sesen Bio (Nasdaq: SESN ) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow , chief executive officer of Trevena, Inc., and
|
|
Jan 31, 2020
|
Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that it has granted non-statutory stock options to purchase an aggregate of 85,500
|
